Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Gilead Sciences stock last closed at $112.97, up 0.36% from the previous day, and has increased 42.19% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.56 percentage points. Gilead Sciences stock is currently +45.32% from its 52-week low of $77.74, and -7.27% from its 52-week high of $121.83.
There are currently 1.24B GILD shares outstanding. The market value of GILD is $140.17B. In the last 24 hours, 4.63M GILD shares were traded.
You will need an online brokerage account to access the NASDAQ market and buy GILD stock.
Based on our research, eToro is the best brokerage. eToro gives you:
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've picked the right brokerage, you need to fill out some personal details so you can invest in GILD today.
Now that you've filled out your info on one of the most highly reviewed stock market apps, you can securely and quickly fund your account:
Watch the tutorial below to see the process of transferring funds into your new investment account.
After you have decided on the best place to buy Gilead Sciences stock, it's crucial to research their stock prior to buying, so you truly wrap your head around the risk and opportunity.
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on GILD's stock page.
You can use many financial metrics, analyses, models, and charts to gauge GILD's intrinsic value.
Using relative valuations measures:
You can access additional valuation analysis on GILD's stock here.
Out of 12 Wall Street analysts who monitor GILD, the consensus analyst rating on Gilead Sciences is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Hartaj Singh, a bottom 2% analyst from Oppenheimer maintains GILD with a buy rating and lowers their GILD price target from $132.00 to $125.00, on Apr 25, 2025.
Matthew Harrison, a top 26% analyst from Morgan Stanley maintains GILD with a strong buy rating and raises their GILD price target from $130.00 to $135.00, on Apr 25, 2025.
Morgan Stanley's Matthew Harrison raised their price target on Gilead Sciences (NASDAQ: GILD) by 3.8% from $130 to $135 on 2025/04/25. The analyst maintained their Strong Buy rating on the stock.
Gilead Sciences reported its Q1 2025 earnings.
"The company delivered a generally in-line quarter," Harrison told readers.
Noting that negotiations with the FDA about lenacapavir for PREP are proceeding as planned, management restated its FY 2025 guidance, the analyst added.
With the advancement of the company's next-generation HIV program, Harrison predicted additional multiple expansion and perhaps upward revisions to lenacapavir estimates.
For Q1 2025, Gilead Sciences reported:
For FY 2025, management guided:
Chairman & CEO Daniel O’Day commented: “Gilead had a strong start to the year, driven by excellent commercial and clinical execution along with disciplined expense management.
“Our base business grew 4% Y/Y, primarily led by Biktarvy’s continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first-line PD-L1+ metastatic triple negative breast cancer.
“With the upcoming 2025/06 PDUFA date for lenacapavir for HIV prevention, and continued progress across our diverse pipeline, we look forward to building on our positive momentum throughout the year.”
Carter Gould, a top 16% analyst from Cantor Fitzgerald assumes GILD with a strong buy rating and announces their GILD price target of $125.00, on Apr 22, 2025.
Evan Seigerman, a bottom 11% analyst from BMO Capital maintains GILD with a buy rating and raises their GILD price target from $115.00 to $120.00, on Apr 17, 2025.
Chris Schott, a top 22% analyst from JP Morgan maintains GILD with a strong buy rating and raises their GILD price target from $120.00 to $130.00, on Mar 27, 2025.
You can dive deeper into what analysts are saying on the Gilead Sciences stock forecast page.
Last year, GILD earnings were $6.31B. In the past 4 year, GILD's earnings have increased by 5.22% per year. This was slower than the Drug Manufacturers - General industry average of 6.07%.
Last year, GILD revenue was $28.86B. In the past 5 year, GILD's revenue has gone up by 5.41% per year. This was slower than the Drug Manufacturers - General industry average of 9.87%.
Dive into GILD's earnings and revenue performance here.
In the last year, insiders at GILD have sold more shares than they have bought.
Daniel Patrick Oday, Chairman CEO of GILD, was the latest GILD insider to sell. They sold $1,136,300.00 worth of GILD stock on Aug 28, 2025.
Get more info about who owns GILD stock here.
Gilead Sciences pays a dividend of 2.76%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.03%. If you owned $1,000 worth of GILD stock, you would have been paid $27.62 last year.
Gilead Sciences dividend payments have consistently grown over the past decade and have remained stable.
Find more info about Gilead Sciences dividend yield and history here.
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
There are two primary options:
Press the Open Trade button and your broker will execute your order.
If you want additional assistance buying stocks on eToro, click the helpful video below:
Now that you own some GILD stock, you'll want to stay up-to-date on your new stock purchase.
Put GILD on a watchlist to track your GILD stock.
To reiterate, here are the 6 steps to buy stock in Gilead Sciences:
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get updates on your investment in Gilead Sciences, create your watchlist below.